HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Policy

Teva scores in appeal as court revives $177M verdict against Lilly in migraine patent spat

The legal back-and-forth over migraine meds from Teva and Eli Lilly has resurfaced, with Teva gaining favor on appeal after a 2023 defeat.

By FiercePharma · Apr 17, 2026 · via FiercePharma
Teva scores in appeal as court revives $177M verdict against Lilly in migraine patent spat

Image: FiercePharma

Tags
policyformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
Roivant’s CEO thinks China is a ‘red herring’
PolicyFierceBiotech ↗
Roivant’s CEO thinks China is a ‘red herring’
China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma ex…
Apr 18, 2026
AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’
PolicyFierceBiotech ↗
AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’
Asked by Fierce if he'd consider returning to the FDA, Pazdur said he wouldn't serve again under the Trump adm…
Apr 18, 2026
Trump Administration Again Blocks UNFPA Funding Under Kemp-Kasten
PolicyBriefing
Trump Administration Again Blocks UNFPA Funding Under Kemp-Kasten
Using the Kemp-Kasten amendment, the administration withheld $32.5 million in FY2025 UNFPA support and is expe…
Apr 17, 2026